Volver a Agendas
Session Chair(s)
Osamu Komiyama
Senior Manager, Statistical Research & Data Science
Pfizer R&D Japan G.K., Japan
Rei Maeda
Consultant
Independent Consultant for Drug PV, Japan
Speaker(s)
Benefit-Risk Assessment - introduction to quantitative approach (MCDA) -
Akihiro Nakajima
Teijin Pharma Limited, Japan
Pharmaceutical Development Administration Department
Recent Progress in Benefit-Risk Evaluation Methodology and Practices: An Industry Perspective
Filip Mussen, PhD
Janssen R&D, Pharmaceutical Companies of Johnson & Johnson, Belgium
Vice President, Regional Regulatory Affairs
Xavier Luria, MD
(DDR) Drug Development and Regulation, Spain
Chair and Senior Consultant
¿Tiene una cuenta?